Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI71FN)

Drug Name
EDO-S101 Drug Info
Synonyms
Tinostamustine; Minomustine; 1236199-60-2; UNII-29DKI2H2NY; 29DKI2H2NY; Tinostamustine [USAN]; SCHEMBL7915449; CHEMBL3989941; EDO-S-101; EDO-S 101; MolPort-046-033-566; EX-A1322; ZINC68244536; AKOS030526024; CS-6484; HY-101780; EDO-S101,1236199-60-2, EDO-S101,EDO S101,EDOS101; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Haematological malignancy 2B33.Y Phase 1 [1]
Cross-matching ID
PubChem CID
46836227
CAS Number
CAS 1236199-60-2
TTD Drug ID
DMI71FN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histone deacetylase (HDAC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [2]
Sodium phenylbutyrate DMXLBCQ Spinal muscular atrophy 8B61 Approved [3]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [1]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [4]
Pracinostat DMTD7AB Acute myeloid leukaemia 2A60 Phase 3 [5]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [6]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [1]
CMS-024-02 DMC4X7L Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
Abexinostat DM91LGU Follicular lymphoma 2A80 Phase 3 [8]
PDX-101 DM6OC53 Plasma cell myeloma 2A83.1 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase (HDAC) TTBH0VX NOUNIPROTAC Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
3 Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
6 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
7 US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
8 Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
9 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.